Week 14 and still nauseated most of the week. How do I tell titration nausea from a persistent problem?

Fourteen weeks in, currently at the second-to-top dose, and I have been told repeatedly that the nausea settles. It has not settled. It has changed shape.

Weeks 1-6 were a clear pattern: bad for a week after each step, then fine. That matched everything I read. Since about week nine the pattern has gone: I am mildly queasy on five or six days out of seven, I have lost the good end of the week, and twice I have had episodes bad enough that I did not eat for most of a day.

Weight loss has been good, about 11% so far, and I do not want to lose that. But I also notice I am organising my life around this, and I have started declining things because of how I expect to feel.

What I actually want to know: is there a defensible way to distinguish "still titrating, be patient" from "this dose is not tolerable for me and the answer is not more time"? And is a lower maintenance dose a real option or a euphemism for giving up on the result?

On the mitigations, since they will be suggested to you and the evidence base behind them is very uneven. Sorted by how much support there actually is, which is not the order in which they are usually recommended.

Reasonable evidence, or strong mechanistic grounds plus consistent reports

• Slower escalation and dose holding. The best-supported intervention by a wide margin, with randomised within-trial evidence from the dose-finding programmes that escalation rate drives GI event rates. This is the one thing on the list with a genuine trial signal behind it.
• Reducing fat per meal. Strong mechanistic basis: dietary fat is the most potent physiological inhibitor of gastric emptying, and you are already on a drug that inhibits it. Consistently reported as the highest-yield dietary change. Note this is fat per meal, not fat per day.
• Reducing meal volume and increasing meal frequency. Same mechanism, addresses the gastric capacity constraint directly.
• Maintaining fluid intake. Not a treatment for nausea so much as a way of not amplifying it. Also the intervention that prevents the tolerability problem becoming a renal one.
• Avoiding recumbency for a couple of hours after eating. Targets the reflux component, which is a real fraction of reported nausea.

Weak evidence, low risk, plausibly worth trying

• Ginger. Has some evidence in pregnancy-related and chemotherapy-related nausea, at doses around 1 g per day of powdered rhizome, which is far more than a ginger biscuit contains. No evidence whatsoever in this specific context. Cheap, low risk.
• Peppermint, cold foods, bland foods, dry starches. Purely symptomatic, no trial evidence, universally reported to help. The mechanism for cold food is odour: heat volatilises the smell compounds that trigger the response.
• Acupressure wristbands. Evidence in other nausea contexts is equivocal at best. Harmless.
• Vitamin B6. Evidence in pregnancy-related nausea. No reason to think it transfers, and high chronic doses carry a peripheral neuropathy risk, so the dose matters.

Prescription antiemetics: a clinician's decision, with real caveats

Ondansetron, metoclopramide, prochlorperazine and others are sometimes prescribed for this. Three things worth understanding before assuming they are a free fix:

• Ondansetron is constipating, and constipation on this class is already common and outlasts the nausea. Trading one GI symptom for another is a real outcome, not a theoretical one.
• Metoclopramide is a prokinetic, which sounds ideal for delayed gastric emptying, but it carries a tardive dyskinesia risk that limits duration of use, and it is not a long-term strategy.
• Suppressing a symptom that is your only signal of overexposure is not obviously wise. If nausea is telling you the dose is above your tolerable exposure, medicating the signal and continuing to escalate is a way of arriving somewhere worse without warning.

Things with no evidence that get recommended anyway

• Changing injection site to reduce nausea. Absorption differences between abdomen, thigh and upper arm are modest for these agents and there is no evidence they change the emetic response. People report it works; the obvious confound is that they changed sites at a point in the cycle when symptoms were declining anyway.
• Changing injection day so that the worst days fall on a weekend. Does not reduce anything, but it is a genuinely sensible piece of scheduling and worth doing for that reason alone.
• Splitting a weekly dose into smaller more frequent injections. Theoretically reduces peak-to-trough variation, which could plausibly help. No human evidence in this context, and it introduces handling and arithmetic risk. Also worth noting that with a one-week half-life the peak-to-trough ratio is already modest, so there is less to be gained than the intuition suggests.
• Antacids and proton pump inhibitors for the emetic component. They will help genuine reflux, which is worth doing, but they do nothing for area postrema signalling and are frequently taken in the expectation that they will.

The honest summary: one intervention has trial evidence and it is going slower. Everything else is mechanism plus report, which is not nothing, but it should be held loosely.

A point on the framing of the original question, since it contains an assumption worth surfacing: that the 11% loss is a thing to be protected and the nausea is a cost to be borne.

Look at what the trials actually did with people in your position. They did not keep them at the top dose. Every protocol in this class permits dose reduction or extended titration for intolerability, and a meaningful fraction of participants used it. The published mean weight-loss figures are therefore already inclusive of people who reduced or held their dose. The 20.9% in the SURMOUNT-1 15 mg arm is not the result achieved by people who all took 15 mg uneventfully; it is the result in a randomised arm that included holds and reductions. Trial results are not achieved by ignoring tolerability. They are achieved by managing it.

Second: your two days of not eating are not a tolerability footnote. Two days in five weeks means your intake is being determined by symptoms rather than by intent, and that has consequences that do not show up on the scale for months:

• Protein intake on a day you cannot eat is close to zero, and repeated zero-protein days on a substantial energy deficit is one of the more reliable ways to lose lean mass rather than fat mass.
• Fluid and electrolyte intake go with it.
• Weight loss on those days is disproportionately water and glycogen, which reads as good progress and is not.

Third, the thing nobody quantifies: you have started declining commitments. No trial has that as an endpoint, which is a limitation of the trials rather than a sign that it does not matter. If the question is whether the current dose is worth it, the answer depends on a quantity the safety tables do not contain.

None of this is an argument against the drug or for stopping. It is an argument that the dose is a parameter, not a target, and that the version of this that you are still doing in three years is worth more than the version that produces 1.4 extra percentage points of mean weight reduction while you organise your week around feeling ill.